<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04953871</url>
  </required_header>
  <id_info>
    <org_study_id>89403766-604.01.02-147611</org_study_id>
    <nct_id>NCT04953871</nct_id>
  </id_info>
  <brief_title>Enthesitis Assessment Before and After Anti-Tumor Necrosis Factor Treatment in Spondyloarthritis</brief_title>
  <official_title>Clinical and Ultrasonographic Enthesitis Assessment Before and After Anti-Tumor Necrosis Factor Treatment in Patients With Spondyloarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gunay ER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Biological therapies should be considered in patients with high disease activity despite&#xD;
      nonsteroid antiinflammatory drug treatment. The first option among biological therapies is&#xD;
      anti-Tumor Necrosis Factor (anti-TNF) drugs. In recent years, anti-TNF treatments have shown&#xD;
      that clinical and ultrasonographic enthesitis may improve as well as disease activity,&#xD;
      quality of life and acute phase reactants. In this prospective study, we aimed to evaluate&#xD;
      the clinical and ultrasonographic evaluation of enthesitis and to determine its response to&#xD;
      anti-TNF treatment in patients with SpA.In this prospective study, we aimed to evaluate the&#xD;
      clinical and ultrasonographic evaluation of enthesitis and to determine its response to&#xD;
      anti-TNF treatment in patients with SpA.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Actual">January 2018</completion_date>
  <primary_completion_date type="Actual">September 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>All patients were evaluated by the researcher who had a 10-year experience of musculoskeletal ultrasonography and is blind to clinical evaluation.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>change from ultrasonographic entesitis score at 3 months</measure>
    <time_frame>before and 3 months after anti-TNF treatment</time_frame>
    <description>Madrid Sonographic Enthesitis Index was used to screen etheseal sites</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from disease activity</measure>
    <time_frame>before and 3 months after anti-TNF treatment</time_frame>
    <description>Bath Ankylosing Spondylitis Disease Activity Index was used</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from disease activity</measure>
    <time_frame>before and 3 months after anti-TNF treatment</time_frame>
    <description>Ankylosing Spondylitis Disease Activity Score was used</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from quality of life</measure>
    <time_frame>before and 3 months after anti-TNF treatment</time_frame>
    <description>Ankylosing Spondylitis Quality of Life was used</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Functionality</measure>
    <time_frame>before and 3 months after anti-TNF treatment</time_frame>
    <description>Bath Ankylosing Spondylitis Functionality Index was used</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Spondyloarthritis</condition>
  <condition>Enthesitis</condition>
  <condition>Anti-Tumor Necrosis Factor Drugs</condition>
  <arm_group>
    <arm_group_label>Spondyloarthritis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Spondyloarthritis patients who was initiated TNF alfa blocker</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TNF Inhibitor</intervention_name>
    <description>TNF inhibitors are widely used in patients with spondyloarthritis</description>
    <arm_group_label>Spondyloarthritis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Spondyloarthritis patients were diagnosed according to 2009 Assessment of&#xD;
             Spondyloarthritis International Society (ASAS) criteria&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe cardiovascular and respiratory diseases,&#xD;
&#xD;
          -  Severe liver and kidney failure,&#xD;
&#xD;
          -  Pregnancy and lactation,&#xD;
&#xD;
          -  Active infection,&#xD;
&#xD;
          -  Malignancy,&#xD;
&#xD;
          -  Demyelinating diseases,&#xD;
&#xD;
          -  Systemic lupus erythematosus,&#xD;
&#xD;
          -  History of knee, elbow, foot and ankle surgery,&#xD;
&#xD;
          -  Fluoroquinolone, retinoid and fluoride use,&#xD;
&#xD;
          -  Local corticosteroid injection at the examination sites within the six weeks before&#xD;
             evaluation&#xD;
&#xD;
          -  Peripheral neuropathy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 22, 2021</study_first_submitted>
  <study_first_submitted_qc>July 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 8, 2021</study_first_posted>
  <last_update_submitted>July 2, 2021</last_update_submitted>
  <last_update_submitted_qc>July 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization</investigator_affiliation>
    <investigator_full_name>Gunay ER</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylarthritis</mesh_term>
    <mesh_term>Enthesopathy</mesh_term>
    <mesh_term>Necrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tumor Necrosis Factor Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

